The association between urinary placental protein 13 and soluble fms-like tyrosine kinase-1 in preeclamptic women in the third trimester of pregnancy

Authors

  • Nesreen A. Nasser Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq
  • Rayah S. Baban Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq
  • May F. Al-Habib Department of Anatomy, Histology and Embryology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
  • Risala A. Jameel Ministry of Health, Al-Immamain Al-Kadhimain Medical City, Baghdad, Iraq

DOI:

https://doi.org/10.47419/bjbabs.v1i01.31

Keywords:

galectin 13, placental protein 13, PP13, preeclampsia, soluble fms-like tyrosine kinase-1

Abstract

Background: Preeclampsia (PE) is diagnosed after 20 weeks of gestation. This multisystem disorder affects 2-7% of pregnant women. PE is a serious complication of pregnancy and one of the main causes of maternal and neonatal mortality and morbidity in the world. The inadequate placentation process results in a change in anti-angiogenic factors levels, such as placental protein 13 (PP13) and soluble fms-like tyrosine kinase 1 (sFlt-1).

Objectives: To investigate the correlation between urinary PP13 and sFlt-1 in preeclamptic women in their third trimester of pregnancy.

Methods: A case-control study was carried out from August 2018 till January 2019. Urine samples were collected from pregnant women at Al-Elweyia Hospital, Al-Hakeem Hospital, and Al- Imamain Al-Kadhimain Medical City (in Baghdad, Iraq). The patients’ group include fifty women with PE in the third trimester (25 mild and 25 severe). Fifty healthy pregnant women (at their third trimester of pregnancy) were studied as a control group.

Results: The mean urinary PP13 levels were decreased in women with PE significantly (p≤ 0.05) (mild and severe) compared with healthy women (43.44±4.914 pg/ml, 33.34±1.863 pg/ml, and 51.84 ±2.60 pg/ml) respectively. Also, urinary sFlt-1 concentrations were decreased non-significantly (p> 0.05) in women with PE (mild and severe) compared with healthy women (5.71±0.414 ng/ml, 5.31±0.38 ng/ml and 6.01±0.282 ng/ml), respectively.

Conclusions: Urinary PP13 and sFlt-1 levels in the third trimester of pregnancy were significantly correlated with the severity of PE, and urinary levels of PP13 were found to be decreased significantly in patients with PE than in healthy pregnant women in the 3rd trimester of pregnancy.

Downloads

Download data is not yet available.

References

ACOG. “ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia”. Obstet Gynecol 133(1) (2019), p. 1. DOI: 10.1097/AOG.0000000000003018.

Elizabeth A. Phipps et al. “Pre-eclampsia: pathogenesis, novel diagnostics and therapies”. Nat Rev Nephrol 15(5) (2019), pp. 275–289. DOI: 10.1038/s41581-019-0119-6.

Jane Hitti et al. “Contribution of hypertension to severe maternal morbidity”. Am J Obstet Gynecol 219(4) (2018), 405.e1–405.e7. DOI: 10.1016/j.ajog.2018.07.002.

Jeffry Iman Gurnadi et al. “Difference of concentration of placental soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy”. BMC Res Notes 8(1) (2015), p. 534. DOI: 10.1186/s13104-015-1506-0.

Jenny L. Sones and Robin L. Davisson. “Preeclampsia, of mice and women”. Physiol Genomics 48(8) (2016), pp. 565–572. DOI: 10.1152/physiolgenomics.00125.2015.

K. H. Nicolaides et al. “A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound”. Ultrasound Obstet Gynecol 27(1) (2006), pp. 13–17. DOI: 10.1002/uog.2686.

M Sammar et al. “Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy”. Int J Mol Sci 20 (2019). DOI: 10.3390/ijms20133192.

Ping Tang et al. “Use of serum and urinary soluble sFlt-1 and PLGF in the diagnosis of preeclampsia”. Hypertens Pregnancy 36(1) (2017), pp. 48–52. DOI: 10.1080/10641955.2016.1237642.

R Gadde, C D Dayanand, and S R Sheela. “Placental protein 13: An important biological protein in preeclampsia”. J Circ Biomark 7 (2018), pp. 1–16. DOI: 10.1177/1849454418786159.

Ron Maymon et al. “Developing a new algorithm for first and second trimester preeclampsia screening in twin pregnancies”. Hypertens Pregnancy 36(1) (2017), pp. 108–115. DOI: 10.1080/10641955.2016.1242605.

Stefan C Kane. “First trimester screening for pre-eclampsia”. Obstet Med 9(3) (2016), pp. 106–112. DOI: 10.1177/1753495x16649074.

Tammy Hod, Ana Sofia Cerdeira, and S. Ananth Karumanchi. “Molecular mechanisms of preeclampsia”. Cold Spring Harb Perspect Med 5(10) (2015), a023473–a023473. DOI: 10.1101/cshperspect.a023473.

Vincent Dupont et al. “Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill coronavirus disease 2019 patients”. Arch Clin Infect Dis (2020), pp. 1834–1837. DOI: 10.1093/cid/ciaa1007.

Warren Stevens et al. “Short-term costs of preeclampsia to the United States health care system”. Am J Obstet Gynecol 217(3) (2017), 237–248.e16. DOI: 10.1016/j.ajog.2017.04.032.

Downloads

Published

2020-12-31

How to Cite

Nasser, N., Baban, R., Al-Habib, M., & Jameel, R. (2020). The association between urinary placental protein 13 and soluble fms-like tyrosine kinase-1 in preeclamptic women in the third trimester of pregnancy. Baghdad Journal of Biochemistry and Applied Biological Sciences, 1(01), 48–53. https://doi.org/10.47419/bjbabs.v1i01.31

Most read articles by the same author(s)